A Phase 3 interventional study of rivaroxaban in Portal Vein Thrombosis, sponsored by Sherief Abd-Elsalam. Status unknown at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2017-10-13.
Sponsored by Sherief Abd-Elsalam · Phase 3, Interventional, and Treatment
-Rivaroxaban is factor Xa inhibitor
PVT is a common complication of liver cirrhosis
1,506 studies on the registry are indexed under Thrombosis; 238 are open to participants now.
This study's planned enrollment of 40 is below the median of 106 across 849 interventional studies indexed under Thrombosis.
Browse Thrombosis studies →Sherief Abd-Elsalam is the lead sponsor of 50 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
rivaroxaban
Drug: rivaroxaban
rivaroxaban
Also known as: xarelto
Number of patients with recanalized portal vein
recanalization of portal vein
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sherief Abd-Elsalam